The Essential Role of Nuclear β-Catenin Translocation in the Osteoblastic Differentiation of GCTB: Prediction of Tumor Ossification After Denosumab Treatment

Atsushi Kimura
Kyushu University

Yu Toda
Kyushu University

Yoshihiro Matsumoto (ymatsu@ortho.med.kyushu-u.ac.jp)
Kyushu University

Hidetaka Yamamoto
Kyushu University

Kenichiro Yahiro
National Kyushu Medical Center

Eijiro Shimada
Kyushu University

Masaya Kanahori
Kyushu University

Suguru Fukushima
National Cancer Centre

Makoto Nakagawa
Kyushu University

Nokitaka Setsu
Kyushu University

Makoto Endo
Kyushu University

Toshifumi Fujiwara
Kyushu University

Tomoya Matsunobu
Kyushu Rosai Hospital

Yoshinao Oda
Kyushu University

Yasuharu Nakashima
Kyushu University
Abstract

Denosumab is a game-changing drug for giant cell tumor of bone (GCTB); however, its clinical biomarker regarding tumor ossification of GCTB has not been elucidated. In this study, we investigated the relationship between Wnt/β-catenin signaling and the ossification of GCTB and evaluated whether endogenous nuclear β-catenin expression predicted denosumab-induced bone formation in GCTB. Genuine patient-derived primary GCTB tumor stromal cells exhibited osteoblastic characteristics. Identified osteoblastic markers and nuclear β-catenin translocation were significantly upregulated via differentiation induction and were inhibited by treating with Wnt signaling inhibitor, GGTI-286, or selective Rac1-LEF inhibitor, NSC23766. Furthermore, we reviewed the endogenous ossication and nuclear β-catenin translocation of 86 GCTB clinical samples and elucidated that intra-tumoral ossication was significantly associated with the nuclear translocation. Three-dimensional quantitative analyses (n = 13) of tumoral CT images have revealed that the nuclear β-catenin translocation of naïve GCTB samples was significantly involved with the denosumab-induced tumor ossication. Our findings suggest a close relationship between the nuclear β-catenin translocation and the osteoblastic differentiation of GCTB. Investigations of the nuclear β-catenin in naïve GCTB samples may provide a promising biomarker for predicting the ossication of GCTB following denosumab treatment.

Introduction

Giant cell tumor of bone (GCTB) is a bone neoplasm characterized by locally aggressive and massive bone destruction. The chief components of GCTB are osteoclast-like giant cells (GCTB-OCs) that express RANK and fibroblast-like spindle stromal cells that express RANKL, a key mediator of osteoclast activation. Recently, Histone 3.3 G34W (H3G34W), a driver mutation in H3 histone family member 3A (encoded by H3F3A), was identified as a specific surrogate marker of GCTB. The presence of this mutation confirmed that GCTB stromal cells (GCTB-SCs) are the actual neoplastic component of this tumor.

Surgical resection has been the treatment of choice for GCTB. However, curative resection for GCTB in the axial skeleton (spine, sacrum, and pelvis) is not often feasible. Denosumab, a fully human monoclonal antibody that inhibits RANKL, was recently approved for the treatment of GCTB. Denosumab inhibits RANKL, thereby preventing RANK–RANKL interactions, resulting in deletion of GCTB-OCs and decreasing tumor-induced osteolysis. In addition, diffuse bone formation with the peripheral sclerotic rim is often observed after denosumab treatment. These histological and clinical consequences can result in a more comfortable operative procedure and decrease surgical morbidity. However, the underlying mechanism of that ossification was not known.

Although osteolysis is the characteristic feature of GCTB, intra-tumoral and peripheral bone develops in 30–50% of cases of GCTB. Consistent with this observation, several previous studies reported that GCTB-SCs have the ability to undergo osteoblastic differentiation. One essential requirement
for osteoblastic differentiation could be the association between WNT/β-catenin signaling and its target gene, Runx-related transcription factor2 (RUNX2)\textsuperscript{23–25}. Previous studies reported nuclear β-catenin translocation and expression of RUNX2 in GCTB-SCs\textsuperscript{21,26}. These results suggest the involvement of the so-called "canonical" Wnt signaling pathway in the osteoblastic differentiation of GCTB-SCs. However, this hypothesis has remained unproven\textsuperscript{7}, and no useful markers have been identified to predict bone formation in GCTB.

In this study, we investigated the relationship between the Wnt/β-catenin signaling, a critical pathway for osteogenic differentiation, and ossification of GCTB using patient-derived primary cultures. In addition, we investigated whether nuclear β-catenin translocation in GCTB-SCs predicted bone formation after denosumab treatment.

**Results**

**Denosumab induced bone formation in the patient with GCTB**

In patients with GCTB, administration of denosumab often induced massive bone formation, as shown in Figures 1a and 1b. Histologically, we observed loss of GCTB-OCs with marked bone formation (Figures 1c and 1d). Meanwhile, H3G34W-positive GCTB-SCs remained adjacent to or within the newly formed bone (Figures 1e and 1f), suggesting that GCTB-SCs were of the osteoblast lineage, as previously reported\textsuperscript{1,5,27}.

**Isolation of GCTB-SCs and induction of bone differentiation**

To assess the osteogenic potential of GCTB-SCs, we harvested primary cultures from freshly sorted samples (pGCTB-SCs). As shown in Figure 1g, almost all pGCTB-SCs were positive for H3G34W, demonstrating that the cultures were pure. Next, we grew pGCTB-SCs in the presence or absence of OGM. The presence of OGM strongly stimulated ALP expression in pGCTB-SCs in a time-dependent manner (Figures 1h and S1a). This induction of ALP expression was not abolished by the removal of OGM, indicating that the osteoblastic differentiation was irreversible (Figure S1b). In addition, the mRNA levels for representative osteoblast genes *ALP*, *COL1A1*, *IBSP* (bone sialoprotein), *RUNX2*, and *BGLAP* (osteocalcin) were significantly increased by the presence of OGM (Figure 1i) in a time-dependent manner (Figure S1c). Fluorescence immunocytochemical analysis revealed that H3G34W-positive pGCTB-SCs expressed high levels of ALP after OGM treatment (Figure 1j). Based on these findings, we confirmed that H3G34W-positive pGCTB-SCs had the capacity to differentiate into bone-forming osteoblasts.

**Effect of the activation of Wnt/β-catenin signaling on osteoblastic differentiation of pGCTB-SCs**

The osteoblastic differentiation from mesenchymal precursors is regulated by the Wnt and BMP signaling pathways\textsuperscript{23,28–30}. In addition, previous studies reported nuclear β-catenin translocation in GCTB-SCs\textsuperscript{31}. Hence, we hypothesized that the canonical Wnt pathway regulates the osteoblastic differentiation of pGCTB-SCs. Accordingly, we grew pGCTB-SCs in OGM, lysed the cells, and purified
cytoplasmic and nuclear protein fractions. By western blotting, we confirmed that the nuclear β-catenin translocation was upregulated within 12 hours after OGM treatment, although cytoplasmic β-catenin remained unchanged (Figures 2a and 2b). To further determine whether the nuclear β-catenin translocation was due to activation of the canonical Wnt pathway, we treated pGCTB-SCs with LiCl or the anti-sclerostin antibody romosozumab, both of which activate canonical Wnt signaling. Interestingly, treatment with those Wnt pathway agonists did not induce ALP expression in pGCTB-SCs (LiCl; Figures 2c and 2d, romosozumab; Figures 2e and 2f, respectively).

**Inhibition of the nuclear β-catenin translocation by geranylgeranyltransferase inhibitor abolished osteoblastic differentiation of pGCTB-SCs**

Next, we studied the effect of GGTI-286 (GGTI), a recently identified Wnt/β-catenin pathway inhibitor, on the osteoblastic differentiation of pGCTB-SCs. GGTI dramatically decreased OGM-induced ALP expression in pGCTB-SCs in a dose-dependent manner (Figures 3a and 3b). GGTI also significantly abolished the osteoblastic makers' expression (ALP, COL1A1, IBSP, and RUNX2; Figure 3c). We also confirmed that GGTI inhibited the OGM-induced nuclear β-catenin translocation in a dose-dependent manner (Figure 3d). The immunocytochemical analysis also revealed that GGTI abrogated the OGM-induced nuclear β-catenin translocation in pGCTB-SCs (Figure 3e). These results suggested that the nuclear β-catenin translocation was indispensable for osteoblastic differentiation of pGCTB-SCs.

**Activation of Rac1 was required for osteoblastic differentiation of pGCTB-SCs**

We then investigated the underlying mechanism by which GGTI inhibited the OGM-induced nuclear β-catenin translocation. A previous study claimed that GGTI binds a geranylgeranyl group on the C terminus of Rho family small GTPases, including Rac1. Furthermore, Rac1 promotes the nuclear β-catenin translocation through phosphorylation at Ser191 by a downstream effector kinase, JNK. Hence, we analyzed the effect of a selective Rac1-GEF inhibitor, NSC23766 (NSC), on OGM-induced osteoblastic differentiation of pGCTB-SCs. Like GGTI, NSC also decreased the expression levels of ALP and other osteoblastic markers in pGCTB-SCs following OGM treatment (Figures 4a-c). NSC also diminished nuclear β-catenin translocation following OGM treatment (Figures 4d and S1d). Together, these findings indicate that activation of Rac1 is required for the nuclear β-catenin translocation and subsequent osteoblastic differentiation of pGCTB-SCs.

**Nuclear β-catenin translocation in GCTB-SCs of patients with GCTB and its association with intra-tumoral ossification of GCTB**

Some cases of GCTB exhibit spontaneous intra-tumoral ossification, whereas others do not. Based on our *in vitro* results, we hypothesized that in cases in which endogenous nuclear β-catenin translocation occurs in GCTB-SCs, the tumor cells might be more likely to differentiate into osteoblasts. To test this notion, we first assessed the distribution of NLBI in GCTB-SCs using 91 clinical samples of GCTB. Of those samples, three cases were excluded due to overlap, one was removed due to low sample
quantity, and another was excluded because the associated patient data were not available. Ultimately, a total of 86 tumor sections were retrospectively reviewed. The background data on these sections are presented in Supplemental Table 1. A retrospective evaluation revealed that the distribution of NBLI in GCTB-SCs was variable, ranging from 0% to 76.4% (median: 13.5%, Figure 5a). In addition, the histogram of NBLI in GCTB-SCs exhibited a non-normal distribution (Figure 5b). We set the median as the cut-off value of the NBLI and subdivided the cases of GCTB into two groups as follows: positive (NBLI > 13.5%, positive group, n = 43) and negative for nuclear β-catenin translocation (NBLI ≤ 13.5%, negative group, n = 43). Retrospective evaluation of NBLI significantly coincided among reviewers (R² = 0.877 by Pearson product-moment correlation coefficient; P < 0.0001, Figure S2). When we examined the prevalence of intra-tumoral ossification of GCTB, we found that 42 out of 86 samples (48.8%) developed intra-tumoral ossification (Figures 5c and 5d), consistent with a previous report 20. Remarkably, the positive group exhibited a significantly higher rate of intra-tumoral ossification (Figure 5e) than the negative group (Figure 5f), as shown in Figure 5g (P < 0.0001, Fisher's exact test).

The number of GCTB-SCs with nuclear β-catenin translocation in biopsy samples was correlated with the degree of bone formation after denosumab treatment

The diversity of endogenous nuclear β-catenin translocation in GCTB-SCs may explain differences in bone formation after denosumab treatment. To address this issue, we studied 14 consecutive cases of GCTB that received denosumab. One case was excluded due to a problem with the specimen; the remaining 13 tumor samples were reviewed. Detailed information on individual cases is summarised in Table 1.

We first investigated the NBLI in GCTB-SCs of the cases and found seven positive and six negative. Case #5, a positive group representative, exhibited massive bone formation after denosumab treatment, as revealed in CT images (Figures 6a and 6b). Histologically, deletion of osteoclastic giant cells and prominent bone formation was observed (Figures 6c and 6d). However, H3G34W-positive GCTB-SCs were still present in the specimen (Figures 6e and 6f). Biopsy samples acquired before denosumab treatment revealed that multiple GCTB-SCs were positive for nuclear β-catenin translocation (NBLI = 23.9, Figure 6g). Meanwhile, in case #10, a typical case of the negative group, bone formation after denosumab treatment was scarce (Figures 6h and 6i). Additionally, the surgically resected samples exhibited loss of osteoclast-like giant cells but not bone formation (Figures 6j and 6k). However, stromal cells were positive for H3G34W, as were the biopsy samples (Figures 6l and 6m). Importantly, before denosumab treatment, only a few GCTB-SCs were positive for nuclear β-catenin translocation (NBLI = 8.5, Figure 6n).

We next quantified denosumab-induced bone formation using CT images, as described previously 36. In the window setting where the tumor margins were discernible, ROIs for histogram analyses were semi-automatically delineated by tracing the tumors' outer margins before (Figures 7a–7g) and after (Figures 7i–7o) denosumab treatment. The entire, peripheral, and intra-tumor Agatston scores of the GCTBs were obtained by histogram analyses using SYNAPSE VINCENT (Figures 7h and 7p). Notably, after denosumab administration, the positive group exhibited significantly higher ossification than the negative group.
group (Figures 7q–7s). Therefore, the positive group would have more chances to undergo denosumab-induced bone formation. Thus, the NBLI in GCTB-SCs in biopsy samples represents a reasonable and straightforward biomarker for predicting the degree of bone formation after denosumab treatment.

**Discussion**

The introduction of denosumab has attracted attention as a novel therapy of GCTB. Several clinical studies have confirmed that denosumab administration prevents osteolysis, concomitant with the deletion of GCTB-OCs\(^{15,16,18,37}\). It may also cause additional histological consequences, including central sclerosis with peripheral bone formation, enabling surgical downstaging. However, the degree of bone formation is case-dependent, and we experienced some cases with little bone formation despite the treatment. Therefore, we assumed that predicting subsequent bone formation after denosumab administration would have clinical benefits for decision making, enabling clinicians to achieve optimal treatment for GCTB.

We first focused on the mechanism of osteoblastic differentiation of GCTB-SCs. H3G34W-positive GCTB-SCs had the ability to differentiate into osteoblasts but not chondrocytes or adipocytes (data not shown), indicating that GCTB-SCs did not retain pluripotency. During osteoblastic differentiation, the canonical Wnt/\(\beta\)-catenin signaling is the dominant pathway\(^{26}\). However, in our study, forced activation of LRP- and GSK3\(\beta\)-mediated canonical Wnt/\(\beta\)-catenin signaling did not cause differentiation. By contrast, our results showed that the apparent nuclear \(\beta\)-catenin translocation was associated with the osteoblastic differentiation of GCTB-SCs and that a recently identified inhibitor of the canonical Wnt signaling, GGTI, effectively inhibited it.

GGTI inhibits protein prenylation, and this process is essential for the correct localization and functions of GTPases, including Rac1\(^{32}\). In addition, Rac1 stimulates nuclear \(\beta\)-catenin translocation through phosphorylation at Ser191 by a downstream effector kinase, JNK\(^{27}\). Consistent with these previous results, we found that Rac1 inhibition suppressed nuclear \(\beta\)-catenin translocation and osteoblastic differentiation of GCTB-SCs. Therefore, we considered that denosumab administration caused activation of Rac1 and triggered the nuclear localization of \(\beta\)-catenin, followed by osteoblastic differentiation of GCTB-SCs, ultimately resulting in the cessation of tumor activity. If this is the case, forced activation of Rac1 in GCTB-SCs by a potent Rac1-agonist, such as the recently discovered natural polyketide deacetylmycoepoxydiene\(^{38}\), may stimulate the osteoblastic differentiation of GCTB-SCs, and combination treatment with denosumab and Rac1-agonist could be an effective strategy for the treatment of GCTB.

We detected baseline nuclear \(\beta\)-catenin translocation in pGCTB-SCs, indicating intrinsic activation of canonical Wnt/\(\beta\)-catenin signaling. Interestingly, a previous study showed that miR-125a stimulates the translocation of \(\beta\)-catenin in GCTB-SCs through GSK3\(\beta\)-mediated canonical signaling, resulting in cell proliferation and tumorigenicity\(^{39}\). However, extrinsic inhibition of GSK3\(\beta\) by LiCl did not play significant roles in osteoblastic differentiation of GCTB-SCs, as shown in Figures 2C and 2D. Together, we
speculated that in GCTB of naïve status, there was a baseline activation of canonical Wnt signaling that regulates the proliferation of GCTB-SCs. Meanwhile, denosumab administration may cause Rac1-associated activation of the canonical Wnt/β-catenin pathway by unknown factors.

Several stimuli can elicit Rac1 activation. For example, both Wnt-5a (a Wnt family member) and Ror2 (receptor tyrosine kinase-like orphan receptor2, a dominant receptor of Wnt-5a) activate Rac1 and induce differentiation of human mesenchymal stem cells into osteoblasts. Expression of the Wnt inhibitor secreted frizzled-related protein (sFRP) in GCTB-OCs has been confirmed by comprehensive mRNA profiling of GCTB-SCs. More importantly, we observed expression of Wnt-5a in GCTB-SCs (data not shown). Based on these findings, we hypothesized that deletion of GCTB-OCs by denosumab might decrease the level of sFRP in tumor tissues, activate a cascade of Wnt-5a/Ror2/Rac1 signaling, and finally cause the osteoblastic differentiation of GCTB-SCs.

As another essential feature of this study, we found that endogenous nuclear β-catenin translocation was associated with osteoblastic differentiation of GCTB-SCs via denosumab treatment. Besides, upregulated NBLI was correlated with endogenous intra-tumoral bone formation in GCTB. Notably, a recent epigenetic analysis showed that GCTB-SCs could be classified into three groups, S1 to S3. S1 cells are characterized by the expression of osteoblast-associated genes such as osteopontin, whereas S3 cells have markers of the myofibroblastic lineage, e.g., alpha-smooth muscle actin. S2 cells have features intermediate between those of S1 and S3 cells. Therefore, we speculated that GCTB-SCs with nuclear β-catenin translocation would correspond to S1 cells and be partly committed to differentiation into osteoblasts. Therefore, as discussed in a previous paragraph, the deletion of GCTB-OCs by denosumab triggered the cells’ final osteoblastic differentiation. However, this notion should be further investigated.

This study had several limitations. First, the precise mechanism by which Rac1 activation occurs in GCT-SCs following denosumab treatment was not fully elucidated. More detailed in vitro experiments, including co-cultures of GCTB-SCs and GCTB-OCs, are needed to clarify this issue. Secondly, it is problematic to investigate the small number of cases that received denosumab in a retrospective analysis. To further validate the ability of the NBLI in GCTB-SCs to predict bone formation after denosumab treatment, we plan to conduct more extensive prospective studies in the future.

**Conclusion**

In summary, our findings suggest a close relationship between the nuclear β-catenin translocation via Rac1 activation and the osteoblastic differentiation of GCTB. Investigations of NBLI in naïve GCTB samples will provide a promising biomarker for predicting the degree of bone formation after denosumab treatment.

**Materials And Methods**

**Reagents**
Monoclonal rabbit anti-H3G34W antibody (clone RM263) was purchased from RevMab Biosciences (San Francisco, CA, USA). Monoclonal rabbit anti-β-catenin antibody (#32572), anti-alkaline phosphatase, tissue non-specific antibody (#126820), goat anti-rabbit IgG H&L preadsorbed (Alexa Fluor® 488, #150081), and goat anti-mouse IgG H&L preadsorbed (Alexa Fluor® 594, #150120) were purchased from Abcam (Cambridge, UK). Monoclonal mouse anti-actin clone C4 (MAB1501) was purchased from Merck Millipore (Burlington, MA, USA). A selective inhibitor of geranylgeranyltransferase1, GGTI-286 (#22756), was purchased from Cayman Chemical (Ann Arbor, MI, USA), and a selective Rac1 (a Rho-family small GTPase) inhibitor, NSC23766, was purchased from Merck Millipore.

Establishment of primary culture and treatment

Some fresh GCTB tumor samples were obtained from surgeries and washed with warmed PBS. The samples were minced in DMEM (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% FBS (HyClone Laboratories, Logan, UT, USA), 100 U/ml penicillin, and 100 μg/ml streptomycin. Together with small pieces of chipped tissues, the cell suspension was transferred to culture dishes and cultured at 37°C in a humidified atmosphere of 5% CO₂ and 95% air. GCTB-OCs were present only in the first passage, whereas primary GCTB-SCs (pGCTB-SCs) were further amplified. Upon reaching confluence, pGCTB-SCs were sub-cultured, and the third through sixth passages were used for subsequent experiments. To induce osteogenic differentiation, confluent cells were treated with osteogenic medium (OGM) containing Minimum Essential Medium (Thermo Fisher Scientific) supplemented with 10% FBS, 100 nM dexamethasone (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan), 100 μM ascorbic acid (FUJIFILM Wako), and 10 mM β-glycerophosphoric acid (NACALAI TESQUE, INC., Kyoto, Japan) for various periods.

Preparing cell brocks and immunocytochemistry of GCTSCs

To determine the purity of primary cultures, we prepared cell blocks and performed immunostaining with anti-H3G34W. Confluent suspensions of pGCTB-SCs were harvested, and cell pellets were prepared by centrifugation for 5 minutes at 1,500 rpm. The pellets were incubated overnight at 37°C in DMEM, and then fixed for 3 hours at room temperature (RT) in 10% Formalin Neutral Buffer Solution (FUJIFILM Wako). After fixation, the supernatant was aspirated, and 1% sodium alginate (FUJIFILM Wako) was added to the pellets. Gelatinous cell blocks were immediately obtained by addition of 100 μl of 1 M CaCl₂ (FUJIFILM Wako), and the blocks were embedded in paraffin.

Immunostaining was performed as described previously 43. Briefly, antigen retrieval of deparaffinized sections was performed with 10 mM citric acid pH 6.0 (FUJIFILM Wako), and then the samples were incubated with anti-H3G34W monoclonal Abs (1:200) at 4°C overnight 44. Specimens were then incubated with Dako EnVision Dual Link System-HRP (Agilent, Santa Clara, CA, USA), visualized using the diaminobenzidine substrate system (FUJIFILM Wako), and counterstained with hematoxylin 44. Section images were obtained on a Keyence BZ-X800 microscope (Keyence Corporation, Osaka, Japan).
Alkaline phosphate staining

ALP activity is widely used to assess the early osteogenic ability of osteoblast-like cells. We seeded pGCTB-SCs into a 24-well plate at a density of $5 \times 10^4$ cells per well. After 48 hours of incubation, the culture medium was exchanged and further incubated for the indicated periods. The cells were washed with PBS, fixed in 10% formalin, and stained with premixed ALP substrate solutions (FUJIFILM Wako).

pGCTB-SCs were seeded into 96-well plates at a density of $5 \times 10^3$ cells per well and incubated for 48 hours. After the cells reached confluence, the medium was exchanged, and the samples were incubated further. ALP assays were performed using the TRACP & ALP assay kit (Takara Bio, Kusatsu, Shiga, Japan). Briefly, treated cells were lysed in extraction solution (saline with 1% NP-40), mixed with freshly prepared p-nitrophenyl phosphate substrate (12.5 mM), and incubated at 37°C for 30 minutes. The optical density of p-nitrophenol at 405 nm was determined using iMark™ Microplate Absorbance Reader (Bio-Rad, Hercules, CA, USA). Finally, ALP activity was normalized with a standard curve derived from *Escherichia coli* C75 (Takara Bio).

Quantitative real-time PCR (qRT-PCR)

Total RNA of treated pGCTB-SCs was extracted using the RNeasy Mini Kit (Qiagen, Hilden, Germany) and reverse-transcribed with PrimeScript RT Reagent Kit (Takara Bio). qRT-PCR was conducted with a LightCycler 1.5 (Perfect Real Time, Takara Bio, Kusatsu, Shiga, Japan) as previously described. Primers are listed in Supplementary Table 2. Data were standardized against the housekeeping gene *GAPDH*. At least four separate experiments were conducted.

Immunofluorescence staining

pGCTB-SCs were seeded on poly-L-lysine (Fujifilm Wako)–coated cover glass at a density of $10 \times 10^4$ cells and cultured for 48 hours. After the cells were treated with each reagent for the indicated periods, they were fixed with 4% paraformaldehyde (FUJIFILM Wako) for 10 minutes at RT, permeabilized with 0.2% Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA) for 15 minutes, and blocked with 10% goat serum (FUJIFILM Wako) for 30 minutes. Subsequently, the cells were incubated at 4°C overnight with a mixture of primary antibodies diluted in 1:200 in Can Get Signal Immunostain Solution A (TOYOBO, Osaka, Japan). Samples were then washed three times with PBS and incubated with Alexa Fluor® 488 and 594 diluted in 1:200 for 1 hour at RT. SlowFade Diamond antifade mountant with DAPI (Invitrogen) was used as a mounting solution. Immunostaining was visualized using fluorescence microscopy (BZ-X800; Keyence).

Nuclear protein extraction and Western blot analysis

pGCTB-SCs were seeded in 6-well dishes at a density of $1.2 \times 10^6$ cells/well and incubated overnight. The following day, the culture media were replaced for each reagent, and the cells were incubated for an additional 12 hours. After incubation, the cells were washed twice with ice-cold PBS, scraped, and
Centrifuged. Cytoplasmic and nuclear proteins were isolated using nuclear and cytoplasmic extraction reagents (Thermo Fisher Scientific) to which Cell Lytic M (Sigma-Aldrich) with protease inhibitor cocktail (cOMplete™ Mini: Sigma-Aldrich) were added.

Western blotting was performed as previously described with the following primary antibodies: β-catenin (1:1000) and actin clone C4 (1:5000), with or without rabbit polyclonal Lamin A/C antibody (1:3000, sc-20681; Santa Cruz Biotechnology, Dallas, TX, USA). Relative intensity was calculated using the ratio of each target protein's signal intensity to internal controls' intensity, using ImageJ ver1.52p (NIH, Bethesda, MD, USA).

**Ethics and Guidelines**

Our all methods were conducted in accordance with the Declaration of Helsinki, and written informed consent was obtained from all human subjects.

**Patients and quantitative CT image analysis**

To evaluate nuclear β-catenin translocation in naïve GCTB clinical samples, we performed a retrospective analysis using samples of GCTB registered in the files of the Department of Anatomic and Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. A total of 91 clinical samples of GCTB from 88 patients were prepared for immunohistochemistry. These tumor specimens had been acquired from biopsy or surgeries, and the existence of the H3G34W mutation had been immunohistochemically confirmed. Samples collected after denosumab treatment were excluded from the study.

Immunohistochemical staining and assessment of the nuclear β-catenin labeling index (NBLI) were performed as previously described. Histogram analysis was conducted to calculate the cut-off value for the NBLI. The presence of intra-tumoral ossification of GCTB was also assessed using H&E-stained sections.

Twenty-one patients were diagnosed with GCTB or received treatment for this cancer at our hospital between July 2011 and November 2020. Of those, 18 patients had received denosumab treatment (primary, n = 12; recurrent, n = 4; both, n = 2), and 16 had also undergone non-contrast CT or PET-CT evaluation before and after denosumab treatment. CT DICOM (Digital Imaging and Communications in Medicine) image datasets from identified patients were analyzed using SYNAPSE VINCENT ver6.1 (VINCENT, FUJIFILM Medical Co., Ltd.). A single musculoskeletal radiologist with eight years of experience manually delineated the regions of interest (ROI) in the axial CT images of whole slices, and three-dimensional CT images were semi-automatically acquired. Slice thickness was set at 2 or 5 mm. We identified the calcified tissue volumes (≥130 Hounsfield Units, HU) using VINCENT histogram analysis and quantified tumor calcification using the previously described Agatston scoring system. In addition, we assessed the association between nuclear β-catenin translocation and intra-tumoral ossification of GCTB.
**Statistical analysis**

All experiments were repeated at least three times. Data are presented as means ± SD. Student’s t-test or Wilcoxon’s rank-sum test was used for two-group comparisons. Multiple comparisons were assessed using one-way ANOVA with the Tukey–Kramer post hoc test. Fisher’s exact test was used to examine the significance of the association between the categorical data. All data analyses were performed using the JMP 13 statistical software (SAS Institute, Cary, NC, USA). P < 0.05 was considered statistically significant.

**Data availability**

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Acknowledgments**

This work was supported in part by JSPS KAKENHI (Grant Numbers: JP18K16627 and JP19K16802) from the Japan Society for the Promotion of Science. The role of the funding body was purchase of test reagents in the collection of data.

**Author contributions**

Conception and design: MY, TY, YH, NM, SN; Acquisition of data: KA, TY, KY, SE, KM; Analysis and interpretation of data: MY, YK, SE, KM, NM, SN; Drafting of manuscript: KA, MY; Supervision: OY, NY, FS, NM, FT; The author(s) read and approved the final manuscript.

**Competing interests**

The authors declare no competing interests.

**Ethics approval**

The study was approved by the Institutional Review Board in Kyushu University in Fukuoka, Japan (approval number 26-224).

**References**

1. Huang, L., Teng, X. Y., Cheng, Y. Y., Lee, K. M. & Kumta, S. M. Expression of preosteoblast markers and Cbfa-1 and Osterix gene transcripts in stromal tumour cells of giant cell tumour of bone., 34, 393–401 https://doi.org/10.1016/j.bone.2003.10.013 (2004).

2. Raskin, K. A., Schwab, J. H., Mankin, H. J., Springfield, D. S. & Hornicek, F. J. Giant cell tumor of bone. J Am Acad Orthop Surg, 21, 118–126 https://doi.org/10.5435/JAAOS-21-02-118 (2013).
3. Matsumoto, Y. et al. Role of the VEGF-Flt-1-FAK pathway in the pathogenesis of osteoclastic bone destruction of giant cell tumors of bone. *J Orthop Surg Res*, 5, 85 https://doi.org/10.1186/1749-799x-5-85 (2010).

4. Palmerini, E. et al. Role of (Neo)adjuvant Denosumab for Giant Cell Tumor of Bone. *Current treatment options in oncology*, 21, 68 https://doi.org/10.1007/s11864-020-00766-4 (2020).

5. Noh, B. J. & Park, Y. K. Giant cell tumor of bone: updated molecular pathogenesis and tumor biology. *Hum Pathol*, 81, 1–8 https://doi.org/10.1016/j.humpath.2018.06.017 (2018).

6. Yamamoto, H. et al. Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone. *Hum Pathol*, 73, 41–50 https://doi.org/10.1016/j.humpath.2017.11.020 (2018).

7. Steensma, M. R. et al. Targeting the giant cell tumor stromal cell: functional characterization and a novel therapeutic strategy. *PLoS One*, 8, e69101 https://doi.org/10.1371/journal.pone.0069101 (2013).

8. Salerno, M., Avnet, S., Alberghini, M., Giunti, A. & Baldini, N. Histogenetic characterization of giant cell tumor of bone. *Clin Orthop Relat Res*, 466, 2081–2091 https://doi.org/10.1007/s11999-008-0327-z (2008).

9. Behjati, S. et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. *Nat Genet*, 45, 1479–1482 https://doi.org/10.1038/ng.2814 (2013).

10. Luke, J. et al. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant., 71, 125–133 https://doi.org/10.1111/his.13190 (2017).

11. Fellenberg, J. et al. Knock-down of oncohistone H3F3A-G34W counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells. *Cancer Lett*, 448, 61–69 https://doi.org/10.1016/j.canlet.2019.02.001 (2019).

12. Sobti, A., Agrawal, P., Agarwala, S. & Agarwal, M. Giant Cell Tumor of Bone - An Overview. *The archives of bone and joint surgery*, 4, 2–9 (2016).

13. Cowan, R. W. & Singh, G. Giant cell tumor of bone: a basic science perspective., 52, 238–246 https://doi.org/10.1016/j.bone.2012.10.002 (2013).

14. Lujic, N., Sopta, J., Kovacevic, R., Stevanovic, V. & Davidovic, R. Recurrence of giant cell tumour of bone: role of p53, cyclin D1, beta-catenin and Ki67. *International orthopaedics* 40, 2393-2399, doi:10.1007/s00264-016-3292-2 (2016).

15. Branstetter, D. G. et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. *Clin Cancer Res, 18*, 4415–4424 https://doi.org/10.1158/1078-0432.CCR-12-0578 (2012).

16. Thomas, D. et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. *Lancet Oncol, 11*, 275–280 https://doi.org/10.1016/s1470-2045(10)70010-3 (2010).

17. Urakawa, H. et al. Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study. *World J Surg Oncol,*
16, 160 https://doi.org/10.1186/s12957-018-1459-6 (2018).
18. Ueda, T. et al. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial. *Ann Oncol*, 26, 2149–2154 https://doi.org/10.1093/annonc/mdv307 (2015).
19. Huvos, A. G. *Bone tumors: Diagnosis, treatment and prognosis Second edition* (WB Saunders CBS Educ and Professional Publ, 1987).
20. Fornasier, V. L., Protzner, K., Zhang, I. & Mason, L. The prognostic significance of histomorphometry and immunohistochemistry in giant cell tumors of bone. *Hum Pathol*, 27, 754–760 https://doi.org/10.1016/s0046-8177(96)90445-1 (1996).
21. Kato, I. et al. Giant cell tumors of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses., 72, 914–922 https://doi.org/10.1111/his.13448 (2018).
22. Murata, A., Fujita, T., Kawahara, N., Tsuchiya, H. & Tomita, K. Osteoblast lineage properties in giant cell tumors of bone. *J Orthop Sci*, 10, 581–588 https://doi.org/10.1007/s00776-005-0946-0 (2005).
23. Cai, T. et al. WNT/beta-catenin signaling promotes VSMCs to osteogenic transdifferentiation and calcification through directly modulating Runx2 gene expression. *Experimental cell research*, 345, 206–217 https://doi.org/10.1016/j.yexcr.2016.06.007 (2016).
24. Gaur, T. et al. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. *The Journal of biological chemistry*, 280, 33132–33140 https://doi.org/10.1074/jbc.M500608200 (2005).
25. Komori, T. Runx2, an inducer of osteoblast and chondrocyte differentiation. *Histochem Cell Biol*, 149, 313–323 https://doi.org/10.1007/s00418-018-1640-6 (2018).
26. Wan, Y. et al. beta-catenin is a valuable marker for differential diagnosis of osteoblastoma and osteosarcoma. *Hum Pathol*, 45, 1459–1465 https://doi.org/10.1016/j.humpath.2014.02.022 (2014).
27. Wu, X. et al. Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling., 133, 340–353 https://doi.org/10.1016/j.cell.2008.01.052 (2008).
28. Kim, J. H. et al. Wnt signaling in bone formation and its therapeutic potential for bone diseases. *Ther Adv Musculoskelet Dis*, 5, 13–31 https://doi.org/10.1177/1759720X12466608 (2013).
29. D’Alimonte, I. et al. Wnt signaling behaves as a "master regulator" in the osteogenic and adipogenic commitment of human amniotic fluid mesenchymal stem cells. *Stem cell reviews*, 9, 642–654 https://doi.org/10.1007/s12015-013-9436-5 (2013).
30. Regard, J. B., Zhong, Z., Williams, B. O. & Yang, Y. Wnt signaling in bone development and disease: making stronger bone with Wnts. *Cold Spring Harb Perspect Biol*, 4, https://doi.org/10.1101/cshperspect.a007997 (2012).
31. Matsubayashi, S. et al. Immunohistochemical analyses of beta-catenin and cyclin D1 expression in giant cell tumor of bone (GCTB): a possible role of Wnt pathway in GCTB tumorigenesis. *Pathol Res Pract*, 205, 626–633 https://doi.org/10.1016/j.prp.2009.02.011 (2009).
32. Nishiya, N. et al. A zebrafish chemical suppressor screening identifies small molecule inhibitors of the Wnt/beta-catenin pathway. *Chem Biol*, 21, 530–540 https://doi.org/10.1016/j.chembiol.2014.02.015 (2014).

33. Joyce, P. L. & Cox, A. D. Rac1 and Rac3 are targets for geranylgeranyltransferase I inhibitor-mediated inhibition of signaling, transformation, and membrane ruffling. *Cancer research*, 63, 7959–7967 (2003).

34. Stein, G. S., Lian, J. B., Stein, J. L., Van Wijnen, A. J. & Montecino, M. Transcriptional control of osteoblast growth and differentiation. *Physiol Rev*, 76, 593–629 https://doi.org/10.1152/physrev.1996.76.2.593 (1996).

35. Masui, F., Ushigome, S. & Fujii, K. Giant cell tumor of bone: an immunohistochemical comparative study. *Pathol Int*, 48, 355–361 https://doi.org/10.1111/j.1440-1827.1998.tb03918.x (1998).

36. Agatston, A. S. et al. Quantication of coronary artery calcium using ultrafast computed tomography. *Journal of the American College of Cardiology*, 15, 827–832 https://doi.org/10.1016/0735-1097(90)90282-t (1990).

37. Mak, I. W., Evaniew, N., Popovic, S., Tozer, R. & Ghert, M. A Translational Study of the Neoplastic Cells of Giant Cell Tumor of Bone Following Neoadjuvant Denosumab. *J Bone Joint Surg Am*, 96, e127 https://doi.org/10.2106/JBJS.M.01332 (2014).

38. Xie, W., Zhang, W., Sun, M., Lu, C. & Shen, Y. Deacetylmycoepoxydiene is an agonist of Rac1, and simultaneously induces autophagy and apoptosis. *Appl Microbiol Biotechnol*, 102, 5965–5975 https://doi.org/10.1007/s00253-018-9058-6 (2018).

39. Jin, H. et al. miR-125a Promotes the Progression of Giant Cell Tumors of Bone by Stimulating IL-17A and beta-Catenin Expression. *Mol Ther Nucleic Acids*, 13, 493–502 https://doi.org/10.1016/j.omtn.2018.09.021 (2018).

40. Sonomoto, K. et al. Interleukin-1beta induces differentiation of human mesenchymal stem cells into osteoblasts via the Wnt-5a/receptor tyrosine kinase-like orphan receptor 2 pathway. *Arthritis Rheum*, 64, 3355–3363 https://doi.org/10.1002/art.34555 (2012).

41. Morgan, T. et al. Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. *Am J Pathol*, 167, 117–128 https://doi.org/10.1016/s0002-9440(10)62959-8 (2005).

42. Khazaei, S. et al. H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone. *Cancer Discov*, 10, 1968–1987 https://doi.org/10.1158/2159-8290.CD-20-0461 (2020).

43. Setsu, N. et al. The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas., 118, 1637–1648 https://doi.org/10.1002/cncr.26448 (2012).

44. Yahiro, K. et al. Class III beta-Tubulin Overexpression Induces Chemoresistance to Eribulin in a Leiomyosarcoma Cell Line. *Analytical Cellular Pathology* 2018, 1-11, doi:10.1155/2018/8987568 (2018).
45. Hatano, M. et al. Cadherin-11 regulates the metastasis of Ewing sarcoma cells to bone. *Clin Exp Metastasis, 32*, 579–591 https://doi.org/10.1007/s10585-015-9729-y (2015).

46. Fujiwara-Okada, Y. et al. Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma. *British journal of cancer, 108*, 836–847 https://doi.org/10.1038/bjc.2012.579 (2013).

47. Sato, M. et al. Wnt/beta-catenin signal alteration and its diagnostic utility in basal cell adenoma and histologically similar tumors of the salivary gland. *Pathol Res Pract, 214*, 586–592 https://doi.org/10.1016/j.prp.2017.12.016 (2018).

48. Takahashi, H. et al. Possible role of nuclear beta-catenin in resistance to preoperative chemoradiotherapy in locally advanced rectal cancer., *71*, 227–237 https://doi.org/10.1111/his.13227 (2017).

49. Ricalde, A., Allison, M., Rifkin, D. & Shaw, R. Anthropometric measures of obesity and renal artery calcification: Results from the Multi-Ethnic Study of Atherosclerosis. *Atherosclerosis, 271*, 142–147 https://doi.org/10.1016/j.atherosclerosis.2018.02.031 (2018).

### Tables

**Table 1.** Patient characteristics, with distribution of nuclear beta-catenin and quantification of tumor ossification

| #  | Age/Gender | Site          | Campanacci grade | NBLI (%) | Agatston score<sup>2</sup> |
|----|------------|---------------|------------------|----------|----------------------------|
|    |            |               |                  | Entire   | Peripheral                 | Intra-tumor |
| 1. | 68/F       | Rt. tibia     | II               | 76.4     | 4.75                       | 2.27        | 17.36       |
| 2. | 20/F       | Rt. fibula    | II               | 69.4     | 7.90                       | 4.68        | 14.55       |
| 3. | 28/M       | Lt. femur     | II               | 38.7     | 2.44                       | 2.24        | 3.93        |
| 4. | 41/F       | C-spine       | II               | 30.7     | 5.41                       | 8.50        | 3.01        |
| 5. | 31/M       | Rt. femur     | II               | 23.9     | 67.79                      | 75.19       | 62.60       |
| 6. | 40/M       | L/E           | N/A              | 18.9     | 12.42                      | 26.73       | 6.35        |
| 7. | 84/F       | Rt. humerus   | III              | 18.6     | 3.73                       | 1.99        | 9.36        |
| 8. | 74/F       | Lt. tibia     | III              | 12.6     | 1.06                       | 1.04        | 1.17        |
| 9. | 27/F       | Sacrum        | III              | 10.1     | 1.31                       | 1.45        | 1.05        |
| 10.| 35/M       | Rt. humerus   | III              | 8.5      | 1.55                       | 1.20        | 6.52        |
| 11.| 39/F       | Rt. femur     | III              | 0.0      | 1.20                       | 1.16        | 1.33        |
| 12.| 66/M       | Rt. tibia     | II               | 0.0      | 1.30                       | 1.29        | 1.30        |
| 13.| 18/M       | Rt. humerus   | II               | 0.0      | 1.37                       | 1.15        | 3.05        |

**Abbreviations:** C-spine, cervical spine; L/E, lower extremity (Soft tissue recurrence); Lt, left; NBLI, Nuclear beta-catenin labeling index;

N/A, not acquired due to soft tissue recurrence; Rt, right.
Each Agatston score of post-denosumab treatment was normalized against the pre-treatment score.

**Figures**

![Image](image_url)

**Figure 1**

GCTB stromal cells can differentiate into bone. (a) A radiograph of the affected bone lesion in a patient with GCTB (case #2 in Table 1) shows osteolysis of the right proximal fibula (arrowhead) before denosumab treatment. (b) Distinctive skeletogenesis in the same case (arrowhead) after denosumab treatment. (c,e) H&E and immunohistochemical stainings revealed that multinucleated giant cells were surrounded by abundant mononuclear and anti-Histone 3.3 G34W (H3G34W)-positive GCTB stromal cells (GCTB-SCs). (d, f) One of the remaining focal tumor lesions within the osteoid after denosumab treatment. Anti-H3G34W-positive GCTB-SCs remained adjacent to (arrow) or inside (arrowhead) the osteoid. Scale bar, 50 μm. (g) Established primary cultures of GCTB-SCs (pGCTB-SCs) were diffusely positive for the H3G34W mutation. Scale bar, 50 μm. (h) Cytochemical staining for alkaline phosphatase (ALP) activity. pGCTB-SCs were cultured in the presence or absence of osteogenic medium (OGM) for the indicated periods. The induction of osteoblast differentiation increased ALP activity in a time-dependent manner. (i) pGCTB-SCs exhibited osteoblastic characteristics by differentiation induction. Cells were cultured for the indicated times in OGM, and mRNA expressions of osteoblastic markers, ALP, COL1A1, IBSP (bone sialoprotein), RUNX2, and BGLAP (osteocalcin) were measured by qRT-PCR. Gene expression at each stage is given relative to the level of vehicle (as control). Values represent means ± SD (n = 4). COL1A1, collagen type α1; IBSP; integrin-binding sialoprotein; RUNX2, runt-related transcription factor-2; BGLAP, bone gamma-carboxyglutamate protein. ***P < 0.0001 (j) H3G34W-positive tumor cells retained the ability to differentiate into osteoblasts. Cells were maintained with or without OGM for six days and then double-stained with anti-H3G34W and anti-ALP antibodies. Fluorescence images were observed under a confocal microscope: scale bars, 50 μm.
Figure 2

Nuclear β-catenin translocation (nuclear β-catenin translocation) is essential but not sufficient for bone differentiation of GCTB. (a,b) Induction of bone differentiation increased nuclear β-catenin translocation. pGCTB-SCs were treated with or without OGM for 12 hours, and β-catenin was analyzed in the nuclear and cytoplasmic fractions by western blotting. Lamin A/C was adopted as a loading control for nuclear extracts and actin for cytoplasmic extracts. Experiments were repeated three times, and representative
images were shown. (c, d) LiCl, a canonical Wnt agonist, did not induce ALP expression in pGCTB-SCs. Tumor cells were cultured with 10 or 20 mM LiCl for 1 week, and then cytochemical staining was performed (c). Effects of LiCl on ALP expression of pGCTB-SCs were also evaluated by measuring OD405 (d). (e, f) The anti-sclerostin antibody romosozumab (Rosomo), another canonical Wnt agonist, did not induce ALP expression of pGCTB-SCs. Tumor cells were treated with 100 or 500 μg/ml romosozumab for 1 week, and ALP expression was subsequently evaluated. ***P<0.0001

Figure 3

Inhibition of nuclear β-catenin translocation abolishes osteoblastic differentiation of pGCTB-SCs. (a) GGTI-286 (GGTI), a chemical inhibitor of geranylgeranyltransferase, decreased ALP expression levels in a concentration-dependent manner. pGCTB-SCs were differentiated in OGM with or without GGTI-286 for 6 days, and then ALP staining was performed. DMSO was used as a control. (b) pGCTB-SCs were cultured with or without 10μM or 40μM GGTI for 6 days, and ALP activity was determined. Each measurement was normalized according to the standard curve. Values represent means ± SD (n = 4). (c) GGTI diminished expression of osteoblastic markers, ALP, COL1A1, IBSP, and RUNX2. Cells were cultured with
or without 40μM GGTI for the indicated periods, and the mRNA levels were investigated by qRT-PCR. Gene expression at each stage is given relative to the level in the OGM-free control. Values represent means ± SD (n = 4). ***P < 0.0001 (d) GGTI reduced OGM-induced nuclear β-catenin translocation. pGCTB-SCs were pre-treated with 10 μM or 50 μM GGTI-286 for 12 hours and further incubated with OGM for 12 hours. β-catenin was analyzed in the nuclear and cytoplasmic fractions by western blotting. Experiments were repeated three times, and representative images were shown. (e) Nuclear β-catenin translocation was increased by induction of differentiation and abolished by GGTI, although the accumulation of β-catenin involved in cell–cell adhesion was not inhibited. pGCTB-SCs were cultured in OGM with 30 μM GGTI for 12 hours, and then stained with anti-β-catenin and anti-actin antibodies. Fluorescence images were observed under a confocal microscope: scale bars, 50 μm.
Figure 4

Inhibition of RAC1 disrupts nuclear β-catenin translocation and osteogenic differentiation of pGCTB-SCs. (a) NSC23766 (NSC), a selective RAC1-GEF inhibitor, decreased ALP expression levels in GCTSCs in a concentration-dependent manner. pGCTB-SCs were differentiated in OGM with or without NSC for 6 days, and ALP staining was subsequently performed. (b) pGCTB-SCs were cultured with or without 10μM or 50μM NSC for 6 days, and ALP activity was determined by measuring OD405. Values represent means ±
SD (n = 4). ***P < 0.0001 (c) NSC also diminished expression of osteoblastic markers, ALP, COL1A1, IBSP, and RUNX2. Cells were cultured with or without 50 μM NSC for the indicated periods, and the mRNA levels were investigated by qRT-PCR. Values represent means ± SD (n = 4). ***P < 0.0001 (d) NSC decreased the OGM-induced nuclear β-catenin translocation. pGCTB-SCs were pre-treated with 20 μM or 60 μM NSC for 12 hours and further incubated with OGM for 12 hours. β-catenin was analyzed in the nuclear and cytoplasmic fractions by western blotting. Experiments were repeated three times, and representative images were shown.

Figure 5

Nuclear β-catenin translocation in GCTB-SCs was significantly associated with endogenous ossification of GCTB. (a) Eighty-six clinical GCTB samples were retrospectively reviewed, and the nuclear β-catenin labeling index (NBLI) in the GCTB-SCs was calculated. Three to five hotspots per high-power field were evaluated, depending on the level of nuclear β-catenin expression. The median value (13.5) was set as a cut-off for NBLI. (b) Histogram showing non-normal distribution of NBLI in the GCTB-SCs. The image is
color-coded according to the median value of NBLI (arrow). (c–f) Representative images of GCTB specimens with or without intra-tumoral ossification and the results of immunohistochemistry for β-catenin. A typical massive intra-tumoral ossification with focal tumor region was strongly positive for nuclear β-catenin in the stromal component with the ossified case, whereas osteoclastic giant cells were negative for that (c, e). The stromal components surrounding the remaining giant cells were negative for β-catenin in the non-ossified case (d, f). Scale bar, 50 μm. (g) Violin plots of NBLI of GCTB-SCs depicting the association between the nuclear translocation of β-catenin with intra-tumoral ossification of GCTB. The nuclear β-catenin–positive group exhibited a significantly higher intra-tumoral ossification rate than the negative group (P<0.0001, Fisher’s exact test).

**Figure 6**

Nuclear positivity of β-catenin in GCTB-SCs predicts intra-tumoral bone formation of GCTB after denosumab treatment. (a, b) Axial computed tomography (CT) images (case #5) with no ossification before denosumab treatment (a) and massive bone formation after denosumab treatment (b). The red dashed line represents a tumor area located dorsal to the femoral bone. (c, d) Osteoclastic giant cells disappeared after denosumab treatment, and significant bone formation with residual focal tumor lesions was observed. (e, f) Mononuclear stromal cells were diffusely positive for the H3G34W mutation, whereas osteoclastic giant cells were negative. Transformed cells after denosumab treatment were positively stained for the H3G34W mutation (arrow). (g) A denosumab-naïve tumor specimen exhibited strong nuclear positivity for β-catenin (arrowhead) in GCTB-SCs, whereas giant cells were negative. (h, i) Another axial CT image (case #10) with an osteolytic lesion in the right femoral head (h). Bone formation was scarce despite several administrations of denosumab (i). The red dashed line represents tumor lesions. (j, k) Osteoclastic giant cells disappeared after denosumab treatment (j); however, the specimen consisted mainly of fine reticular fibrosis (k). (l, m) Mononuclear cells before denosumab treatment (l) and transformed cells inside fibrosis after that (m) were positive for H3G34W. (n) Stromal tumor cells were weakly positive for nuclear β-catenin in a poorly ossifying case (arrowhead): scale bars, 50 μm.
Figure 7

Nuclear β-catenin positivity of GCTB-SCs is significantly associated with bone formation after denosumab treatment. To elucidate the relationship between β-catenin stainability and tumoral ossification, we performed quantitative evaluations using SYNAPSE VINCENT. (a–g) Representative images of three-dimensional analysis before denosumab treatment (case #2). ROI in the axial (a, b), coronal (c, d), and sagittal (e, f) CT images were delineated, and the 3D tumor model was automatically

\[ \text{Figure 7} \]

Nuclear β-catenin positivity of GCTB-SCs is significantly associated with bone formation after denosumab treatment. To elucidate the relationship between β-catenin stainability and tumoral ossification, we performed quantitative evaluations using SYNAPSE VINCENT. (a–g) Representative images of three-dimensional analysis before denosumab treatment (case #2). ROI in the axial (a, b), coronal (c, d), and sagittal (e, f) CT images were delineated, and the 3D tumor model was automatically
depicted (g). (h) Histogram image of the ROI before denosumab treatment. Tissue volumes with more than 130 HU were identified as significant calcifications, and Agatston scoring was performed as previously described [27, 28]. (i–n) Representative three-dimensional image after the treatment. ROI in the axial (i, j), coronal (k, l), and sagittal (m, n) CT images were used for 3D model analysis (o). Bright yellow lines represent the peripheral rim of the ROI. (p) Histogram image of the ROI after denosumab treatment. In the ossified case, the histogram image was leptokurtic, and the degree of skew was significant. (q–s) The relationship between nuclear β-catenin stainability and intra-tumoral ossification was evaluated using Agatston score (n = 13). The stainability was significantly associated with the score in the entire (q), peripheral (r), and intra-tumoral areas (s) (**P = 0.003 for entire and peripheral tumor, and *P = 0.02 for intra-tumor of GCTB). Each post-treatment Agatston score was normalized against the corresponding pre-denosumab score.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementalFigure.pdf